Fernand Bteich

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/1d179b90-1ebe-11ee-ade4-51ee977c0616.jpg

First Name

Fernand

Last Name

Bteich

NPI

1770004269

Faculty ID

17724

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

123082

Biography

<p>Fernand Bteich, MD, is an attending physician and Assistant Professor, Medicine at Montefiore Einstein. His clinical focus centers on gastrointestinal malignancies, hepatobiliary cancers, colorectal cancer and clinical trials.</p><p>After earning his Medical Doctorate at Saint Joseph University in Beirut, Lebanon in 2015, Dr. Bteich completed his internship at H&ocirc;teI-Dieu de France Hospital in Beirut in 2017. Following this, he completed his internal medicine residency at Saint Louis University in 2020 before completing a hematology-oncology fellowship at Montefiore Einstein in 2023.</p><p>Dr. Bteich&rsquo;s research focuses on hepatobiliary cancers, retrospective outcomes and clinical trials. His work has been published in numerous peer-reviewed scientific publications and he has presented nationally and internationally.</p><p>Dr. Bteich is board certified by the Educational Commission for Foreign Medical Graduates. He is fluent in English, Arabic and French.</p>

Is Open Scheduling

Off

Changcheng Zhu

https://assets.montefioreeinstein.org/profiles/images/Zhu_Changcheng_MD_2x.jpg

First Name

Changcheng

Last Name

Zhu

NPI

1407936909

Faculty ID

10578

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Thoracic pathology, Head &amp; Neck Pathology, Gynecological Pathology and Lung Transplant Pathology<br /><quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Lung cancer<br />

Elsevier Profile

EMR ID

4827

Is Open Scheduling

Off

Michael Yee

https://assets.montefioreeinstein.org/profiles/images/13771-michael-yee.jpg

First Name

Michael

Last Name

Yee

NPI

1699971085

Faculty ID

13771

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

5456

Is Open Scheduling

Off

Kathleen D. Whitney

https://assets.montefioreeinstein.org/profiles/images/physphoto/Whitney_Kathleen_D_MD_3514.jpg

First Name

Kathleen

Last Name

Whitney

NPI

1821178328

Faculty ID

6789

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

3851

Is Open Scheduling

Off

Marc Vimolratana

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/58a00310-6a8c-11ec-afc2-e529147b8d1e.jpg

First Name

Marc

Last Name

Vimolratana

NPI

1467870683

Faculty ID

17157

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Vimolratana is a general thoracic surgeon with a clinical focus on thoracic surgical oncology, including minimally invasive surgery for lung and esophageal cancer. His other clinical interests include mediastinal and chest wall tumors, tracheal disorders, thoracic outlet syndrome, and benign esophageal diseases.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Vimolratana&rsquo;s research focuses on improving patient outcomes after complex lung and esophageal surgery. He has shared his findings through publications in peer-reviewed journals and abstracts at national meetings.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

EMR ID

163553

Biography

<p>Marc Vimolratana, MD, MS, is Assistant Professor, Cardiothoracic and Vascular Surgery at Montefiore Einstein. Dr. Vimolratana is a general thoracic surgeon with a clinical focus on thoracic surgical oncology, including minimally invasive surgery for lung and esophageal cancer. His other clinical interests include mediastinal and chest wall tumors, tracheal disorders, thoracic outlet syndrome, and benign esophageal diseases. Dr. Vimolratana takes a patient-centered approach to patient care and is committed to using minimally invasive techniques, including VATS and robotic surgery, whenever possible to minimize surgical trauma and pain for patients.</p><p>Dr. Vimolratana studied chemistry at Yale, earning a Bachelor of Science and Master of Science in 2006. He attended medical school at the University of California, San Francisco, earning a Doctor of Medicine in 2014. After many years in California, he moved to New York for postdoctoral training at NewYork-Presbyterian Hospital/Weill Cornell Medical Center, where he completed a residency in general surgery in 2019, serving as chief resident in his final year. Dr. Vimolratana continued at NewYork-Presbyterian Hospital for fellowship training in cardiothoracic surgery prior to joining the faculty at Montefiore Einstein in 2021.</p><p>Dr. Vimolratana&rsquo;s research focuses on improving patient outcomes after complex lung and esophageal surgery. He has shared his findings through publications in peer-reviewed journals and abstracts at national meetings.</p><p>Dr. Vimolratana is certified by the American Board of Thoracic Surgery and the American Board of Surgery. He is a member of several professional organizations, including the American College of Surgeons, the Society of Thoracic Surgeons and the European Society of Thoracic Surgeons. He has been honored with numerous awards for academic excellence and clinical care.</p>

Is Open Scheduling

Off

Esperanza Villanueva-Siles

https://documentapi-fargate-documentbucket-15qi4tpdvnhlz.s3.amazonaws.com/218/83dd1f30-84f7-11ef-b387-d348df9d586b.jpg

First Name

Esperanza

Last Name

Villanueva-Siles

NPI

1518047018

Faculty ID

10058

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4730

Is Open Scheduling

Off

Amit K. Verma

https://assets.montefioreeinstein.org/profiles/images/Verma_Amit_MD_2x.jpg

First Name

Amit

Last Name

Verma

NPI

1033299524

Faculty ID

10065

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>https://einsteinmed.edu/labs/amit-verma/</p&gt;
<p><strong style="text-align: justify;">Targeting signal transduction in hematologic malignancies</strong><span style="text-align: justify;">:&nbsp;<br /></span><span style="text-align: justify;">Cytokines play important roles in the regulation of normal hematopoiesis and a balance between the actions of hematopoietic growth factors and myelosuppressive factors is required for optimal production of different hematopoietic cell lineages. The myelodysplastic syndromes (MDS) are collections of heterogeneous hematologic diseases characterized by refractory cytopenias due to ineffective hematopoiesis. These preleukemic disorders are common causes of anemia in the elderly and are rapidly increasing in incidence. We have also demonstrated that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways is overactivated in MDS. Our work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. We are trying to study the molecular mechanisms that lead to the activation of these pathways in MDS and are using small molecule inhibitors in mouse models to target these pathways.&nbsp;</span></p>
<p style="text-align: justify;"><strong>Targeting aberrant stem and progenitor cells in myelodysplastic neoplasms:&nbsp;<br /></strong>We have demonstrated that aberrant stem cells persist during morphological remissions and are involved in relapse. We have identified novel targets against MDS/AML stem cells that are being tested in various studies. We are also conducting sequencing/epigenetic analysis of highly purified human stem cells and evaluating the role of these alterations in transformation of MDS to AML.&nbsp;</p>
<p style="text-align: justify;"><strong>Epigenomic analysis of tumors</strong>: <br />We are using high throughput assays to analyze DNA methylation across the genome and have optimized these assays to work with low amounts of DNA. We have successfully used these assays in conducting an integrative analysis of epigenetic and genetic alterations in various tumor models, including MDS, esophageal cancer, pancreatic cancer and renal cell cancer.</p>
<p style="text-align: justify;"><strong>Clinical studies in Myelodysplastic syndromes</strong>: <br />We have a &ldquo;center of excellence&rdquo; clinic for patients with Myelodysplatic syndromes. We offer a variety of clinical trials for these patients.</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Verma is a blood cancer expert, who specializes in the research and treatment of blood cancers.</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients.

Research Focus

Dr. Verma conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma’s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies. 

Elsevier Profile

Lab Website Link

Selected Publications

<ol>
<li><a href="https://pubmed.ncbi.nlm.nih.gov/40424086/&quot; target="_blank">Splicing of erythroid transcription factor is associated with therapeutic response in myelodysplastic syndromes.</a><br/>Aluri S, Ling T, Fraint E, Chakraborty S, Zhang K, Ahsan A, Kravets L, Poigaialwar G, Zhao R, Pradhan K, Cotton A, Bachiashvili K, Yang JI, Budhathoki A, Agarwal B, Gordon-Mitchell S, Carbajal M, Sahu S, Boultwood J, Pellagatti A, Steidl U, Wickrema A, Nandakumar S, Shastri A, Suragani RN, Bowman TV, Crispino JD, Vodala S, <strong>Verma A. J Clin Invest.</strong> 2025 May 27. PMID: 40424086.</li>

<li><a href="https://pubmed.ncbi.nlm.nih.gov/40333990/&quot; target="_blank">Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias.</a><br/>Venkatasubramanian M, Schwartz L, Ramachandra N, Bennett J, Subramanian KR, Chen X, Gordon-Mitchell S, Fromowitz A, Pradhan K, Shechter D, Sahu S, Heiser D, Scherle P, Chetal K, Kulkarni A, Lee D, Zhou J, Myers KC, Tseng E, Weirauch MT, Grimes HL,* Starczynowski DT,* <strong>Verma A</strong>,* Salomonis N.* <strong>Sci Transl Med</strong>. 2025 May 7. PMID: 40333990. *Co Corresponding</li>

<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39316768/&quot; target="_blank">A Weekly Low-Dose Regimen of Decitabine and Venetoclax is Efficacious and Less Myelotoxic in a Racially Diverse Cohort.</a><br />
Goldfinger M, Mantzaris I, Shastri A, Saunthararajah Y, Gritsman K, Sica A, Kornblum N, Shah N, Levitz D, Rockwell B, Shapiro LC, Gupta R, Pradhan K, Xue X, Munoz A, Dhawan A, Fehn K, Comas M, Verceles JA, Jonas BA, Kambhampati S, Shi Y, Braunschweig I, Cooper DL, Konopleva MY, Feldman EJ, <strong>Verma A. <br />
<em>Blood</em></strong>. 2024 Sep 24.PMID: 39316768 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39300320/&quot; target="_blank">Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses.</a><br />
DiNardo CD, Verma D, Baran N, Bhagat TD, Skwarska A, Lodi A, Saxena K, Cai T, Su X, Guerra VA, Poigaialwar G, Kuruvilla VM, Konoplev S, Gordon-Mitchell S, Pradhan K, Aluri S, Hackman GL, Chaudhry S, Collins M, Sweeney SR, Busquets J, Rathore AS, Deng Q, Green MR, Grant S, Demo S, Choudhary GS, Sahu S, Agarwal B, Spodek M, Thiruthuvanathan V, Will B, Steidl U, Tippett GD, Burger J, Borthakur G, Jabbour E, Pemmaraju N, Kadia T, Kornblau S, Daver NG, Naqvi K, Short NJ, Garcia-Manero G, Tiziani S, <strong>Verma A*</strong>, Konopleva M*.<br />
<strong><em>Nat Cancer</em></strong>. 2024 Sep 19. PMID: 39300320 <br />
*CoCorresponding </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/39294495/&quot; target="_blank">Pharmacological restriction of genomic binding sites redirects PU.1 pioneer transcription factor activity.</a><br />
Taylor SJ, Stauber J, Bohorquez O, Tatsumi G, Kumari R, Chakraborty J, Bartholdy BA, Schwenger E, Sundaravel S, Farahat AA, Wheat JC, Goldfinger M, <strong>Verma A</strong>, Kumar A, Boykin DW, Stengel KR, Poon GMK, Steidl U.<br />
<strong><em>Nat Genet</em></strong>. 2024 Sep 18. PMID: 39294495 </li>
<li> <a href="https://pubmed.ncbi.nlm.nih.gov/38521065/&quot; target="_blank">Transcription elongation defects link oncogenic SF3B1 mutations to targetable alterations in chromatin landscape.</a><br />
Boddu PC, Gupta AK, Roy R, De La Peña Avalos B, Olazabal-Herrero A, Neuenkirchen N, Zimmer JT, Chandhok NS, King D, Nannya Y, Ogawa S, Lin H, Simon MD, Dray E, Kupfer GM, <strong>Verma A</strong>, Neugebauer KM, Pillai MM. <strong><em>Mol Cell</em></strong>. 2024 Apr 18;84(8):1475-1495.e18.PMID: 38521065 </li>
<li> Aminov S*, Giricz O*, Melnekoff DT*, Sica RA*, Polishchuk V, Papazoglu C, Yates B, Wang HW, Sahu S, Wang Y, Gordon-Mitchell S, Leshchenko VV, Schinke C, Pradhan K, Aluri S, Sohn M, Barta SK, Agarwal B, Goldfinger M, Mantzaris I, Shastri A, Matsui W, Steidl U, Brody JD, Shah NN^, Parekh S^, <strong>Verma A</strong>^ Immunotherapy-resistant acute lymphoblastic leukemia cells exhibit reduced CD19 and CD22 expression and BTK pathway dependency <em><strong>JCI</strong></em>, 2024 Feb 20 PMID: 38376944 </li>
<li> Thakkar A, Pradhan K, Duva B, Carre&ntilde;o JM, Sahu S, Thiruthuvanathan V, Campbel S, Gallego S, Bhagat TD, Rivera J, Choudhary G, Olea R, Sabalza M, Shapiro LC, Lee M, Quinn R, Mantzaris I, Chu E, Will B, Pirofski LA, Krammer F, <strong>Verma A</strong>*, Halmos B*&nbsp; Study of efficacy and longevity of immune response to 3rd and 4th doses of COVID-19 vaccines in patients with cancer: a single arm clinical trial&nbsp; <em><strong>Elife</strong></em> 2023, Mar 28;12:e83694. PMID: 36975207 </li>
<li> Levitz D, Saunthararajah Y, Fedorov K, Shapiro LC, Mantzaris I, Shastri A, Kornblum N, Sica RA, Shah N, Konopleva M, Gritsman K, Braunschweig I, Cooper DL, Pradhan K, <strong>Verma A,</strong> Feldman EJ, Goldfinger M. A Metabolically Optimized, Noncytotoxic Low-Dose Weekly Decitabine/Venetoclax in MDS and AML. <em><strong>Clin Cancer Res.</strong></em> 2023 Aug 1;29(15):2774-2780. PMID: 37341641. </li>
<li> Choudhary GS, Pellagatti A, Agianian B, Smith MA, Bhagat TD, Gordon-Mitchell S, Sahu S, Pandey S, Shah N, Aluri S, Aggarwal R, Aminov S, Schwartz L, Steeples V, Booher RN, Ramachandra M, Samson M, Carbajal M, Pradhan K, Bowman TV, Pillai MM, Will B, Wickrema A, Shastri A, Bradley RK, Martell RE, Steidl UG, Gavathiotis E, Boultwood J, Starczynowski DT*, <strong>Verma A</strong>*. Activation of targetable inflammatory immune signaling is seen in myelodysplastic syndromes with SF3B1 mutations. <strong>Elife</strong></em>. 2022 Aug 30;11:e78136. PMID: 36040792; PMCID: PMC9427103. </li>
<li>Jasra S, Giricz O, Zeig-Owens R, Pradhan K, Goldfarb DG, Barreto-Galvez A, Silver AJ, Chen J, Sahu S, Gordon-Mitchell S, Choudhary GS, Aluri S, Bhagat TD, Shastri A, Bejan CA, Stockton SS, Spaulding TP, Thiruthuvanathan V, Goto H, Gerhardt J, Haider SH, Veerappan A, Bartenstein M, Nwankwo G, Landgren O, Weiden MD, Lekostaj J, Bender R, Fletcher F, Greenberger L, Ebert BL, Steidl U, Will B, Nolan A, Madireddy A, Savona MR, Prezant DJ, <strong>Verma A</strong>. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster. <strong><em>Nat Med</em></strong>. 2022 Mar 7. PMID: 35256801.</li>
<li>Lee M, Quinn R, Pradhan K, Fedorov K, Levitz D, Fromowitz A, Thakkar A, Shapiro LC, Kabarriti R, Ruiz RE, Andrews EM, Thota R, Chu E, Kalnicki S, Goldstein Y, Loeb D, Racine A, Halmos B, Mehta V, <strong>Verma A</strong>. Impact of COVID-19 on case fatality rate of patients with cancer during the Omicron wave. <strong><em>Cancer Cell.</em></strong> 2022 Feb 22: PMID: 35219358; PMCID: PMC8860706</li>
<li>Shapiro LC, Thakkar A, Campbell ST, Forest SK, Pradhan K, Gonzalez-Lugo JD, Quinn R, Bhagat TD, Choudhary GS, McCort M, Sica RA, Goldfinger M, Goel S, Anampa JD, Levitz D, Fromowitz A, Shah AP, Sklow C, Alfieri G, Racine A, Wolgast L, Greenberger L, <strong>Verma A</strong>*, Halmos B*. *Co-Corresponding Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer. <strong><em>Cancer Cell</em></strong>. 2022 Jan 10;40(1):3-5. PMID: 34838186; PMCID: PMC8595142.</li>
<li>Komrokji RS, Platzbecker U, Fenaux P, Zeidan AM, Garcia-Manero G, Mufti GJ, Santini V, D&iacute;ez-Campelo M, Finelli C, Jurcic JG, Greenberg PL, Sekeres MA, DeZern AE, Savona MR, Shetty JK, Ito R, Zhang G, Ha X, Backstrom JT, <strong>Verma A</strong>. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <strong><em>Leukemia.</em></strong> 2022 Feb 26. PMID: 35220402.</li>
<li>Pinho S, Wei Q, Maryanovich M, Zhang D, Balandr&aacute;n JC, Pierce H, Nakahara F, Di Staulo A, Bartholdy BA, Xu J, Borger DK,<strong> Verma A</strong>, Frenette PS. VCAM1 confers innate immune tolerance on haematopoietic and leukaemic stem cells. <strong><em>Nat Cell Biol</em></strong>. 2022 Feb 24. PMID: 35210567.</li>
<li>Myer PA, Lee JK, Madison RW, Pradhan K, Newberg JY, Isasi CR, Klempner SJ, Frampton GM, Ross JS, Venstrom JM, Schrock AB, Das S, Augenlicht L, <strong>Verma A</strong>, Greally JM, Raj SM, Goel S, Ali SM. The Genomics of Colorectal Cancer in Populations with African and European Ancestry. <strong><em>Cancer Discov.</em></strong> 2022 Feb 17: PMID: 35176763.</li>
<li>Su H, Jiang M, Senevirathne C, Aluri S, Zhang T, Guo H, Xavier-Ferrucio J, Jin S, Tran NT, Liu SM, Sun CW, Zhu Y, Zhao Q, Chen Y, Cable L, Shen Y, Liu J, Qu CK, Han X, Klug CA, Bhatia R, Chen Y, Nimer SD, Zheng YG, Iancu-Rubin C, Jin J, Deng H, Krause DS, Xiang J, <strong>Verma A*</strong>, Luo M*, Zhao X*. Methylation of dual-specificity phosphatase 4 controls cell differentiation. <em><strong>Cell Rep.</strong></em> 2021 Jul 27;36(4):109421. PMID: 34320342. *Co-Corresponding.</li>
<li>Thakkar A, Gonzalez-Lugo JD, Goradia N, Gali R, Shapiro LC, Pradhan K, Rahman S, Kim SY, Ko B, Sica RA, Kornblum N, Bachier-Rodriguez L, McCort M, Goel S, Perez-Soler R, Packer S, Sparano J, Gartrell B, Makower D, Goldstein YD, Wolgast L, <strong>Verma A*</strong>, Halmos B*. Seroconversion rates following COVID-19 vaccination among patients with cancer. <em><strong>Cancer Cell</strong></em>. 2021 Jun 5: PMID: 34133951; PMCID: PMC8179248. *Co-Corresponding</li>
<li>Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Pellagatti A, Boultwood J, Xiong S, Lozano G, <strong>Verma A</strong>, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. <em><strong>Cancer Cell</strong></em>. 2021 Apr 12;39(4):529-547.e7. PMID: 33667384.</li>
<li>Weinreb JT, Ghazale N, Pradhan K, Gupta V, Potts KS, Tricomi B, Daniels NJ, Padgett RA, Oliveira SD, <strong>Verma A</strong>, Bowman TV Excessive R-loops Trigger an Inflammatory Cascade Leading to Increased HSPC Production <em><strong>Dev Cell</strong></em>, 2021, Mar 8;56(5):627-640. PMID: 33651979.</li>
<li>Shapiro LC, Mustafa J, Lombardo A, Khatun F, Joseph F, Gillick K, Naik A, Elkind R, Abreu M, Fehn K, de Castro A, Pradhan K, Binakaj D, Nelson R, Paroder M, Uehlinger J, Gritsman K, Alejandro Sica R, Kornblum N, Shastri A, Mantzaris I, Bachier-Rodriguez L, <strong>Verma A</strong>, Braunschweig I, Goldfinger M. Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population. <em><strong>Bone Marrow Transplant</strong></em>. 2021 Jul;56(7):1761-1763. PMID: 33846558.</li>
<li>Thakkar A, Pradhan K, Jindal S, Cui Z, Rockwell B, Shah AP, Packer S, Sica RA, Sparano J, Goldstein DY, <strong>Verma A</strong>, Goel S, Halmos B Patterns of seroconversion for SARS-CoV2-IgG in patients with malignant disease and association with anti-cancer therapy <em><strong>Nature Cancer</strong></em>, 2021, 2: 392&ndash;399.</li>
<li>Mehta V*, Goel S*, Kabarriti R*, Cole D, Goldfinger M, Acuna-Villaorduna A, Pradhan K, Thota R, Reissman S, Sparano JA, Gartrell BA, Smith RV, Ohri N, Garg M, Racine AD, Kalnicki S, Perez-Soler R, Halmos B*, <strong>Verma A*</strong>. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. <em><strong>Cancer Discov</strong></em>. 2020 Jul;10(7):935-941. PMID: 32357994; PMCID: PMC7334098.</li>
<li>List AF, Sun Z, <strong>Verma A*</strong>, Bennett JM, Komrokji RS, McGraw K, Maciejewski J, Altman J, Cheema PS, Claxton DF, Luger SM, Mattison RJ, Wassenaar T, Artz AA, Schiffer CA, Litzow MR, Tallman MS Lenalidomide-Epoetin Alfa versus Lenalidomide-monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin <em><strong>JCO</strong></em>, 2021, Jan 13: PMID: 33439748 *Corresponding.</li>
<li>COVID-19 and Cancer Consortium. A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance. <em><strong>Cancer Cell</strong></em>. 2020 Dec 14;38(6):761-766. PMID: 33176160; PMCID: PMC7598547.</li>
<li>Kuderer NM, Choueiri TK, et al. Mishra S, Lyman GH, Rini BI, Warner JL; COVID-19 and Cancer Consortium. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <em><strong>Lancet</strong></em>. 2020 Jun 20;395(10241):1907-1918. PMID: 32473681; PMCID: PMC7255743.</li>
<li><strong>Verma A</strong>, Suragani RN, Aluri S, Shah N, Bhagat TD, Alexander MJ, Komrokji R, Kumar R. Biological basis for efficacy of activing receptor ligand traps in myelodysplastic syndromes. <strong>J Clin Invest.</strong> 2020 Feb 3;130(2):582-589. doi: 10.1172/JCI133678. Review. PMID: 31961337</li>
<li>Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, D&iacute;ez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, G&ouml;tze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellstr&ouml;m-Lindberg E, Zeidan AM, Ad&egrave;s L, <strong>Verma A</strong>, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. <strong>N Engl J Med.</strong> 2020 Jan 9;382(2):140-151. PMID: 31914241</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,&nbsp; Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,&nbsp;&nbsp;<strong>Verma A*.</strong>&nbsp;Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts&nbsp;<strong>Elife,</strong>&nbsp;Oct 30;8, 2019, (In Press)* Equal Contribution&nbsp;PMID: 31663852</li>
<li>Santini V, Valc&aacute;rcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B,&nbsp;<strong>Verma A</strong>.&nbsp;Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.&nbsp;<strong>Clin Cancer Res</strong>. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*,&nbsp;<strong>Verma A</strong>*, Starczynowski D*<br />
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies.&nbsp;<strong>Nature Cell Bio</strong>&nbsp;2019&nbsp;May;21(5):640-650&nbsp;* Equal Contribution&nbsp;</li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C,&nbsp;<strong>Verma A</strong>,* Wickrema A*<br />
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis <strong>Cancer Discovery</strong>&nbsp;2019 Jun;9(6):778-795&nbsp;* Equal Contribution</li>
<li>Bhagat TD, Ahrens DV, Dawlaty M, Zou Y, Baddour J, Achreja A, Zhao H, Yang L, Patel N, Kwak C,&nbsp; Choudhary G, Gordon-Mitchell S, Alluri S, Bhattacharyya S, Yu Y, Bartenstein M, Giricz O, Suzuki M, Sohal D, Gupta S, Batra S, Goggins M, Steidl U, Greally J, Agarwal B, Pradhan K, Banerjee D, Nagrath D*, Maitra A*,&nbsp;&nbsp;<strong>Verma A*.</strong>&nbsp;Lactate-mediated Epigenetic Reprogramming Regulates Formation of Pancreatic Cancer-associated Fibroblasts&nbsp;<strong>Elife,</strong>&nbsp;Oct 30;8, 2019, (In Press)* Equal Contribution&nbsp;PMID: 31663852</li>
<li>Santini V, Valc&aacute;rcel D, Platzbecker U, Komrokji RS, Cleverly AL, Lahn MM, Janssen J, Zhao Y, Chiang A, Giagounidis A, Guba SC, Gueorguieva I, Girvan AC, da Silva Ferreira M, Bhagat TD, Pradhan K, Steidl U, Sridharan A, Will B,&nbsp;<strong>Verma A</strong>.&nbsp;Phase II Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes.&nbsp;<strong>Clin Cancer Res</strong>. 2019 Sep 3. PMID: 31481511</li>
<li>Smith M*, Choudhary GS*, Pellagatti A, Choi K, Bhagat TD, Gordon-Mitchell S, Von Ahrens D, Pradhan K, Steeples V , Kim S, Steidl U , Salomonis N , Walter M, Komurov K, Boultwood J*,&nbsp;<strong>Verma A</strong>*, Starczynowski D*<br />
U2AF1 mutations induce oncogenic innate immune pathways by regulating the expression of active IRAK4 isoforms in hematologic malignancies.&nbsp;<strong>Nature Cell Bio</strong>&nbsp;2019 May;21(5):640-650&nbsp;* Equal Contribution&nbsp;</li>
<li>Jeong JJ, Gu X, Nie J, Sundaravel S, Liu H, Kuo W, Bhagat TD, Pradhan K, Cao J, Nischal S, McGraw K, Bhattacharyya S, Bishop M, Artz A, Thirman M, Moliterno AR, Ji P, Levine RL, Godley LA, Steidl U, Beiker J, List AF, Saunthararajah Y, He C,&nbsp;<strong>Verma A</strong>,* Wickrema A*<br />
Cytokine regulated phosphorylation and activation of TET2 by JAK2 in hematopoiesis<br />
<strong>Cancer Discovery</strong>&nbsp;2019 Jun;9(6):778-795&nbsp;* Equal Contribution</li>
<li>Chen J, Kao Y, Sun D, Todorova T, Reynolds D, Narayanagari SR, Montagna C, Will B,&nbsp;<strong>Verma A</strong>*, Steidl U*Myelodysplastic Syndrome Progression to Acute Myeloid Leukemia at the Stem Cell Level&nbsp;<strong>Nature Medicine</strong>&nbsp;2018,&nbsp;Jan;25(1):103-110&nbsp;* Equal Contribution</li>
<li>Shastri A, Choudhary G, Teixeira M, Gordon-Mitchell S, Ramachandra N, Bernard L, Bhattacharyya, S. Lopez, R. Pradhan, K. Giricz, O. Ravipati, G. Wong, L. F. Cole, S. Bhagat, T. D. Feld, J. Dhar, Y. Bartenstein, M. Thiruthuvanathan, V. J.&nbsp; Wickrema, A. Ye, B. H. Frank, D. A. Pellagatti, A. Boultwood, J. Zhou, T. Kim, Y. MacLeod, A. R. Epling-Burnette, P. K. Ye, M. McCoon, P. Woessner, R. Steidl, U. Will, B.&nbsp;<strong>Verma, A.&nbsp;</strong>Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.&nbsp;<strong>J Clin Invest</strong>. 2018 Sep 25. PMID: 30252677</li>
<li>Shah UA, Chung EY, Giricz O, Pradhan K, Kataoka K, Gordon-Mitchell S, Bhagat TD, Mai Y, Wei Y, Ishida E, Choudhary GS, Joseph A, Rice R, Gitego N, Parrish C, Bartenstein M, Goel S, Mantzaris I, Shastri A, Derman O, Binder A, Gritsman K, Kornblum N, Braunschweig I, Bhagat C, Hall J, Graber A, Ratner L, Wang Y, Ogawa S,&nbsp;<strong>Verma A*</strong>, Ye BH*, Janakiram M.* North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.&nbsp;<strong>Blood.</strong>&nbsp;2018 Aug 13. PMID: 30104217 * Equal Contribution</li>
<li>Landgren O*, Zeig-Owens R*, Giricz O*, Goldfarb D, Murata K, Thoren K, Ramanathan L, Hultcrantz M, Dogan A, Nwankwo G, Steidl S, Pradhan K, Hall C, Cohen HW, Jaber N, Schwartz T, Crowley L, Crane M, Irby S, Webber MP,&nbsp;<strong>Verma A*</strong>, Prezant DJ* Multiple Myeloma and Its Precursor Disease among Firefighters Exposed to the World Trade Center Disaster&nbsp;<strong>JAMA Onc</strong>, 2018 Jun 1;4(6):821-827. PMID: 29710195 &nbsp;* Equal Contribution</li>
<li>Kao YR, Chen J, Narayanagari SR, Todorova TI, Aivalioti MM, Ferreira M, Ramos PM, Pallaud C, Mantzaris I, Shastri A, Bussel JB,&nbsp;<strong>Verma A</strong>, Steidl U, Will B. Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag.&nbsp;<strong>Sci Transl Med</strong>. 2018 Sep 12;10(458). PMID: 30209246</li>
<li>Giricz O, Mo Y, Dahlman KB, Cotto-Rios XM, Vardabasso C, Nguyen H, Matusow B, Bartenstein M, Polishchuk V, Johnson DB, Bhagat TD, Shellooe R, Burton E, Tsai J, Zhang C, Habets G, Greally JM, Yu Y, Kenny PA, Fields GB, Pradhan K, Stanley ER, Bernstein E, Bollag G, Gavathiotis E, West BL, Sosman JA,&nbsp;<strong>Verma AK&nbsp;</strong>The RUNX1/IL-34/CSF-1R axis is an autocrinally regulated modulator of resistance to BRAF-V600E inhibition in melanoma.&nbsp;<strong>JCI Insight</strong>. 2018 Jul 25;3(14). PMID: 30046005</li>
<li>Carvajal LA, Ben-Neriah D, Senecal A, Benard L, Thiruthuvanathan V, Yatsenko T, Narayanagari SR, Wheat JC, Todorova TI, Mitchell KM, Kenworthy C, Guerlavais V, Annis DA, Bartholdy B, Will B, Anampa JD, Mantzaris I, Aivado M, Singer RH, Coleman RA,&nbsp;<strong>Verma A</strong>, Steidl U. Dual inhibition of MDMX and MDM2 as a Therapeutic Strategy in Leukemia.&nbsp;<strong>Sci Transl Med</strong>.&nbsp;2018, Apr 11;10(436). PMID: 29643228</li>
<li>Mitchell K, Barreyro L, Todorova TI, Taylor SJ, Antony-Debr&eacute; I, Narayanagari SR, Carvajal LA, Leite J, Piperdi Z, Pendurti G, Mantzaris I, Paietta E,&nbsp;<strong>Verma A</strong>, Gritsman K, Steidl U.&nbsp; IL1RAP potentiates multiple oncogenic signaling pathways in AML.&nbsp;<strong>J Exp Med.</strong>&nbsp;2018 Jun 4;215(6):1709-1727 PMID: 29773641</li>
<li>Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways,&rdquo; &nbsp;<strong>Genome Res</strong>, 2017, Oct 6. PMID: 28986391</li>
<li>Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM,&nbsp; Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Wnt/&szlig;-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome,&rdquo;&nbsp;<strong>Cancer Research</strong>&nbsp;Jul, 2017, PMID: 28684528</li>
<li>Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD,&nbsp;<strong>Verma A</strong>, Steidl U, Gavathiotis E. Direct &ldquo;Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia,&rdquo;&nbsp;&nbsp;<strong>Cancer Cell</strong>&nbsp;2017 Oct 9.PMID: 29017059&nbsp;</li>
<li>Antony-Debr&eacute; I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E,&nbsp;<strong>Verma A</strong>, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U., &ldquo;Pharmacological inhibition of the transcription factor PU.1 in leukemia,&rdquo; &nbsp;<strong>J Clin Invest</strong>&nbsp;2017 Oct 30, PMID: 29083320</li>
<li>Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ,&nbsp;<strong>Verma A*,</strong>&nbsp;Epling-Burnette PK* (*Co-Corresponding), &ldquo;Efficacy of ALK5 Inhibition in Myelofibrosis.&rdquo;&nbsp;&nbsp;&nbsp;<strong>JCI Insight&nbsp;</strong>(In Press)</li>
<li>Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K,&nbsp;<strong>Verma A*,</strong>&nbsp;Susztak K* (*Co-Corresponding), &ldquo;Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer .&rdquo; &nbsp;<strong>JBC&nbsp;</strong>2016, Dec 1. PMID: 2790905</li>
<li>Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A,&nbsp; Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U,&nbsp;<strong>Verma A,</strong>&nbsp; &ldquo;Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.&rdquo;&nbsp;&nbsp;<strong>Cancer Res&nbsp;</strong>2016 Jun 10. PMID: 27287719</li>
<li>Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I,&nbsp; Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;High Prevalence and Allele Burden Independent Prognostic Importance of p53 Mutations in an Inner-City MDS/AML Cohort,&rdquo; &nbsp;<strong>Leukemia&nbsp;</strong>2016 Apr 29. PMID: 27125205</li>
<li>Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ,&nbsp;<strong>Verma A,</strong>&nbsp;Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG. &ldquo;MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.&rdquo;&nbsp;&nbsp;<strong>Nat Commun.</strong>&nbsp;2016 Feb 22;7:10739. PMID: 26898884</li>
<li>Platzbecker U, Wong RS,&nbsp;<strong>Verma A,</strong>&nbsp;Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, G&ouml;tze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A., &ldquo;Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.&rdquo;&nbsp;&nbsp;<strong>Lancet Haematol.</strong>&nbsp;2015 Oct;2(10):e417-26. PMID: 26686043</li>
<li>Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*,&nbsp;<strong>Verma A</strong>*, Wickrema A*. (*Co-Corresponding),&nbsp; &ldquo;Reduced DOCK4 Expression Leads to Erythroid Dysplasia in Myelodysplastic Syndromes.&rdquo;&nbsp;&nbsp;<strong>PNAS</strong>&nbsp;2015; Nov 17;112(46): PMID: 26578796</li>
<li>Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.&rsquo;&nbsp;<strong>Nature Chem Biol</strong>. 2015 Oct 5. PMID: 26436839</li>
<li>PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015 Jul 13. PMID: 26170031</li>
<li>Cabrero M, Yu Y,&nbsp;<strong>Verma A,</strong>&nbsp;Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, &ldquo;Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.&rdquo;&nbsp;<strong>Br J Haematol.</strong>&nbsp;2015 Jun 24. PMID: 26105212</li>
<li>Vardabasso C, Gaspar-Maia A, Hasson D, P&uuml;nzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B,&nbsp;<strong>Verma A,</strong>&nbsp;Mann M, Hernando E, Hake SB, Bernstein E, &ldquo;Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.&rdquo;&nbsp;<strong>Mol Cell.</strong>&nbsp;2015 Jun 3. PMID: 26051178</li>
<li>Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG,&nbsp;<strong>Verma AK,</strong>&nbsp;Platanias LC, &ldquo;Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma&nbsp; Cells.&rdquo;&nbsp;<strong>Mol Cell Biol.</strong>&nbsp;2015 May 26. PMID: 26012550</li>
<li>Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN,&nbsp;<strong>Verma A,</strong>&nbsp;Platanias LC, &ldquo;Central Role of ULK1 in Type I Interferon Signaling.&rdquo;&nbsp;<strong>Cell Reports</strong>&nbsp;2015, Apr 28;11(4):605-17. PMID: 25892232</li>
<li>Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S,&nbsp;<strong>Verma A,</strong>&nbsp;Jaenisch R, Aifantis I, &ldquo;TET1 is a tumor suppressor of hematopoietic malignancy.&rdquo;&nbsp;<strong>Nat Immunol.</strong>&nbsp;2015 Apr 13. PMID: 25867473</li>
<li>Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*,&nbsp;<strong>Verma A*,&nbsp;</strong>&nbsp; *co-corresponding authors, &ldquo;IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015, Mar 25. PMID: 25810490&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li>
<li>Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, J&auml;dersten M, Dolatshad H,&nbsp;<strong>Verma A,</strong>&nbsp;Cross NC, Vyas P, Killick S, Hellstr&ouml;m-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, &ldquo;Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic Syndromes.&rdquo;&nbsp;<strong>Nat Commun.</strong>&nbsp;2015 Jan 9;6:5901. PMID: 25574665&nbsp;</li>
<li>Caescu CI, Guo X, Tesfa L, Bhagat TD,&nbsp;<strong>Verma A,</strong>&nbsp;Zheng D, Stanley ER, &ldquo;Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2015 Jan 8. PMID: 25573988</li>
<li>Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia.&rdquo;&nbsp;<strong>Nature Medicine,</strong>&nbsp;2015 (In Print)</li>
<li>Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Targeting chemokine pathways in esophageal adenocarcinoma.&rdquo;&nbsp;<strong>Cell Cycle.</strong>&nbsp;2014 Nov 1;13(21):3320-7. PMID: 25485576</li>
<li>Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.&rdquo;&nbsp;<strong>Clin Cancer Res.</strong>&nbsp;2014 Jun 10. PMID: 24916699</li>
<li>Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J,&nbsp;<strong>Verma A,</strong>&nbsp;Prabhakar N, Godley LA, &ldquo;TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.&rdquo;&nbsp;<strong>Cell Rep.</strong>&nbsp;2014 May 14. PMID: 24835990</li>
<li>Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J,&nbsp;<strong>Verma AK,</strong>&nbsp;Pellagatti A, Boultwood J, List AF, Williams DA, Ji P., &ldquo;Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2014 Jun 2. PMID: 24891322</li>
<li>Tamari R,&nbsp; Schinke C, Bhagat T, Roth M, Braunschweig I,&nbsp; Will B,&nbsp; Steidl U,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.&rdquo;&nbsp;<strong>Leuk Lymphoma,</strong>&nbsp;2014 Dec;55(12):2901-6.PMID: 24650011</li>
<li>Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A,&nbsp;<strong>Verma A*,</strong>&nbsp;Steidl U, *Co-Corresponding, &ldquo;A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.&rdquo;&nbsp;<strong>Journal of Clinical Investigation</strong>&nbsp;2014 Feb 3 PMID: 24487588</li>
<li>Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B,&nbsp;<strong>Verma A,</strong>&nbsp;Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, &ldquo;High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma.&rdquo;<strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oncogene,</strong>&nbsp;2014 Mar 31 PMID: 24681958</li>
<li>Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, G&oacute;mez-Segu&iacute; I,&nbsp;<strong>Verma AK,</strong>&nbsp;McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, &ldquo;Recurrent genetic defects on chromosome 7q in myeloid neoplasms.&rdquo;<strong>Leukemia</strong>&nbsp;2014 Jan 16. PMID: 24429498</li>
<li>Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B,&nbsp;<strong>Verma A,</strong>&nbsp;He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, &ldquo;Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.&rdquo;&nbsp;<strong>Cell Reports</strong>&nbsp;2013 Dec 24 PMID: 24373966</li>
<li>Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M,&nbsp;<strong>Verma A,</strong>&nbsp;Zheng D, Greally JM, Susztak K, &ldquo;Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.&rdquo;&nbsp;<strong>Genome Biol.</strong>&nbsp;2013 Oct 7;14(10):R108. PMID: 24098934</li>
<li>Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, J&auml;dersten M,&nbsp;&nbsp;<strong>Verma A,</strong>&nbsp;McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, &ldquo;Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.&rdquo;&nbsp;<strong>JCO</strong>&nbsp;2013 Oct 1;31(28):3557-64. PMID: 24002510</li>
<li>Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S,&nbsp;<strong>Verma AK,&nbsp;</strong>&nbsp;&ldquo;Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.&rdquo;&nbsp;&nbsp;<strong>Am J Hematol.</strong>&nbsp;2013 Nov;88(11):E245-9. PMID: 23828763</li>
<li>Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma&nbsp;<strong>A,</strong>&nbsp;Meltzer SJ, Mori Y, &ldquo;Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.&rdquo;&nbsp;<strong>Gut</strong>&nbsp;2013 Sep 2. PMID: 24000294&nbsp;</li>
<li>Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y,&nbsp;<strong>Verma A*,</strong>&nbsp;Das K, *Co-Corresponding,&nbsp; &ldquo;High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.&rdquo;&nbsp;<strong>Genes Chromosome Cancer</strong>&nbsp;2013 Oct 3. PMID: 24123713</li>
<li>Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A,&nbsp;<strong>Verma A,</strong>&nbsp;Fish EN, Platanias LC, &ldquo;Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.&rdquo;&nbsp;&nbsp;<strong>JBC,</strong>&nbsp;2013 Aug 16;288(33):23814-22 PMID: 23814052</li>
<li>Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J;&nbsp;<strong>Verma, A;&nbsp;</strong>&nbsp;&ldquo;Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.&rdquo;&nbsp;<strong>Nucleic Acid Res</strong>&nbsp;2013&nbsp; Sep;41(16):e157 PMID: 23861445</li>
<li>Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD,&nbsp;<strong>Verma A,</strong>&nbsp;Figueroa ME, Melnick A, Roth M, Steidl U, &ldquo;Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.&rdquo;&nbsp;<strong>Nat Immunol.</strong>&nbsp;2013 May;14(5):437-45. PMID: 23563689</li>
<li>Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;miR-21 mediates hematopoietic suppression in MDS by activating TGF-bsignaling.&rdquo;&nbsp;<strong>Blood</strong>&nbsp;2013, Apr 11;121(15):2875-81. PMID: 23390194</li>
<li>Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.&rdquo;&nbsp;<strong>JBC</strong>&nbsp;2013 Mar 29;288(13):8805-14. PMID: 23306203</li>
<li>Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J,<strong>&nbsp;Verma A*,</strong>&nbsp;Singhal S,* Co-Corresponding, &ldquo;Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.&rdquo; &nbsp;<strong>Journal of Immunology</strong>&nbsp;2013 Mar 15;190(6):2966-75. PMID: 23408834</li>
<li>Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J,&nbsp;<strong>Verma A*,</strong>&nbsp;Meltzer SJ*, Co-Corresponding, &ldquo;Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett&rsquo;s Esophagus and Esophageal Adenocarcinoma.&rdquo;&nbsp;<strong>Gastroenterology</strong>&nbsp;2013 May;144(5):956-966. PMID: 23333711</li>
<li>Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms.&rdquo;&nbsp;<strong>Cancer Res,</strong>&nbsp;2012 Dec 27. PMID: 23066032</li>
<li>Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T,&nbsp; Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.&rdquo;&nbsp;<strong>Blood</strong>&nbsp;2012; 120(10):2076-86. PMID: 22753872</li>
<li>Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R,&nbsp;<strong>Verma A,</strong>&nbsp;Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, &ldquo;Randomized, dose-escalation study of the p38&alpha; MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.&rdquo;&nbsp;<strong>Leukemia.</strong>&nbsp;2012 Sep 11. PMID: 23032694</li>
<li>Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, &ldquo;Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2012 Aug 9;120(6):1290-8. PMID: 22723552</li>
<li>Jerez A, Sugimoto Y, Makishima H,&nbsp;<strong>Verma A,</strong>&nbsp;Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP,&nbsp; &ldquo;Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.&rdquo;&nbsp;&nbsp;&nbsp;<strong>Blood.</strong>&nbsp;2012 Jun 21;119(25):6109-17. PMID: 22553315</li>
<li>Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.&rdquo;&nbsp;<strong>Blood.</strong>&nbsp;2012 May 24. PMID: 22627766</li>
<li>Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U,&nbsp;<strong>Verma A.,</strong>&nbsp;&ldquo;Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.&rdquo;&nbsp;<strong>Leuk Lymphoma</strong>.2012 Apr 18.&nbsp; PMID: 22448921</li>
<li>Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL,<strong>&nbsp;Verma A,</strong>&nbsp;Maciejewski JP, McDevitt MA, Moliterno AR, &ldquo;Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.&rdquo;&nbsp;&nbsp;&nbsp;<strong>Haematologica.</strong>&nbsp;2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540</li>
<li>Sharma B, Altman JK, Goussetis DJ,&nbsp;<strong>Verma AK,</strong>&nbsp;Platanias LC, &ldquo;Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535</li>
<li>Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM,&nbsp;<strong>Verma A,&nbsp;</strong>&nbsp;&ldquo;Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Apr 30. PMID: 21532034&nbsp;</li>
<li>Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.&rdquo;&nbsp;<strong>PLOS Genetics</strong>&nbsp;2011 Mar;7(3) PMID: 21483804</li>
<li>L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol,&nbsp; G Mantzaris, A Pellagatti , J Boultwood, LC Platanias, U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and&nbsp;<strong>A Verma,</strong>&nbsp;&ldquo;Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.&rdquo;&nbsp;<strong>Cancer Research</strong>&nbsp;2011 Feb 1;71(3):955-63.PMID: 21189329</li>
<li>Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R,<strong>&nbsp;Verma AK,</strong>&nbsp;Fish EN, Platanias LC, &ldquo;Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.&rdquo;&nbsp;&nbsp;<br />
<strong>J Biol Chem.</strong>&nbsp;2011 Feb 25;286(8):6017-26.PMID: 21149447</li>
<li>Kroczynska B, Joshi S, Eklund EA,&nbsp;<strong>Verma A,</strong>&nbsp;Kotenko SV, Fish EN, Platanias LC, &ldquo;Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFN&lambda; signaling.&rdquo;&nbsp;<strong>J Biol Chem.</strong>&nbsp;2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.</li>
<li>Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC,&nbsp;<strong>Verma A*,</strong>&nbsp;Das B, &ldquo;Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.&rdquo;&nbsp;<br />
<strong>Leuk Lymphoma.</strong>&nbsp;2010 Jun;51(6):1108-14. PMID: 20536349</li>
<li>Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y,&nbsp;<strong>Verma A,</strong>&nbsp;Theil KS, McDevitt MA, Maciejewski JP, &ldquo;Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.&rdquo;&nbsp;<strong>Genes Chromosomes Cancer.</strong>&nbsp;2010 Apr;49(4):390-9. PMID: 20095039</li>
<li>Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, J&auml;dersten M,&nbsp;<strong>Verma A,</strong>&nbsp;Norbury C Hellstr&ouml;m-Lindberg E, Wainscoat JS, Boultwood J, &ldquo;Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.&rdquo;&nbsp;<strong>Leukemia.</strong>&nbsp;2010 Apr;24(4):756-64. PMID: 20220779</li>
<li>Einstein F, Thompson RF, Bhagat TD, Fazzari MJ,&nbsp;<strong>Verma A,</strong>&nbsp;Barzilai N, Greally JM, &ldquo;Cytosine methylation dysregulation in neonates following intrauterine growth restriction.&rdquo;&nbsp;<strong>PLoS One.</strong>&nbsp;2010 Jan 26;5(1):e8887 PMID: 20126273</li>
<li>Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E.,&nbsp;<strong>Verma A.,</strong>&nbsp;Suzuki M., Greally J.M., &ldquo;High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.&rdquo;&nbsp;<strong>Nucleic Acids Res.</strong>&nbsp;2009 Jul;37(12):3829-39.&nbsp;&nbsp; PMID: 19386619</li>
<li>Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.&rdquo;&nbsp;<strong>PLOS One</strong>&nbsp;2008 Aug 13;3(8):e2965&nbsp;&nbsp;&nbsp; PMID: 18698424</li>
<li>Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A,&nbsp;&nbsp; Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A,&nbsp; Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.&rdquo;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<strong>Blood</strong>&nbsp;2008 Oct 15;112(8):3434-43&nbsp; PMID: 18474728</li>
<li>Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.&rdquo; &nbsp;<strong>Leukemia and Lymphoma</strong>&nbsp;2008 Oct;49(10):1963-75</li>
<li>Zhou L, Opalinska J,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.&rdquo;&nbsp;<strong>Cell Cycle&nbsp;</strong>2007<strong>,</strong>&nbsp;1;6(5):534</li>
<li>Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P,&nbsp;Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS,&nbsp;<strong>Verma A,</strong>&nbsp;&ldquo;Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.&rdquo;&nbsp;<strong>Blood&nbsp;</strong>2006, 15;108(13):4170-7</li>
<li><strong>Verma A,</strong>&nbsp;and List A, &ldquo;Cytokine Targets in Myelodysplastic syndromes.&rdquo;&nbsp;<strong>Current Hematology Reports</strong>&nbsp;2005 Nov;4(6):429-35</li>
<li>Deonarain R,&nbsp;<strong>Verma A,</strong>&nbsp;Porter AC, Gewert DR, Platanias LC, Fish EN, &ldquo;Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.&rdquo;&nbsp;<strong>Proc Natl Acad Sci USA.</strong>&nbsp;2003 Nov 11;100(23):13453-8</li>
<li><strong>Verma A,</strong>&nbsp;Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, &ldquo;Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.&rdquo;&nbsp;&nbsp;<strong>Bone Marrow Transplant.</strong>&nbsp;2003 May;31(9):813-6.</li>
<li><strong>Verma A.,</strong>&nbsp;Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L., &ldquo;Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.&rdquo;&nbsp;&nbsp;<strong>Journal of Biological Chemistry</strong>&nbsp;22;277(47):44988-95</li>
<li><strong>Verma A,</strong>&nbsp;Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L., &ldquo;Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.&rdquo;&nbsp;<strong>Journal of Immunology</strong>&nbsp;2002, 168 (12) (Cutting edge section)</li>
<li><strong>Verma A,</strong>&nbsp;Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, &ldquo;Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor-b on normal hematopoiesis.&rdquo;&nbsp;<strong>Journal of Biological Chemistry</strong>&nbsp;2002, 277(10):7726-35</li>
<li>Devine S, Hoffman R,&nbsp;<strong>Verma A,</strong>&nbsp;Shah R, Bradlow B, Stock W and Van Besien K, &ldquo;Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.&rdquo;<strong>&nbsp;Blood&nbsp;</strong>&nbsp;2002, 99(6):2255-8</li>
</ol>
<p><strong>Review articles</strong></p>
<ol start="1" type="1">
<li>Li W, Morrone K, Kambhampati S, Will B, Steidl U,&nbsp;<strong>Verma A,&nbsp;</strong>&ldquo;Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.&rdquo;&nbsp;<strong>Leukemia,&nbsp;</strong>2015 (In Press)</li>
<li>Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K,&nbsp;<strong>Verma A.,&nbsp;</strong>"Role of DNA methylation in renal cell carcinoma."&nbsp;<strong>J Hematol Oncol.</strong>&nbsp;2015 Jul 22;8(1):88. PMID: 26198328</li>
<li><strong>Verma A,</strong>&nbsp;Steidl U., &ldquo;A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.&rdquo;&nbsp;<br />
<strong>Nat Med.</strong>&nbsp;2015;21:113-4.&nbsp; PMID: 25654599</li>
<li>Ga&ntilde;&aacute;n-G&oacute;mez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS,&nbsp;<strong>Verma A,</strong>&nbsp;Steidl U, Garcia-Manero G, "Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes."&nbsp;<strong>Leukemia.</strong>&nbsp;2015 Mar 12. PMID: 25761935</li>
<li>Shenoy N, Vallumsetla N,&nbsp; Rachmilewitz E,&nbsp;<strong>Verma A,</strong>&nbsp;Ginzburg Y., "Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome."&nbsp;<strong>Blood,</strong>&nbsp;2014 Aug 7;124(6):873-81. PMID: 24923296</li>
<li>Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P,&nbsp;<strong>Verma A,</strong>&nbsp;Ray SK,&nbsp;&nbsp;&nbsp; Evans T.,&nbsp; "Retinoic acid signaling pathways in development and diseases."<br />
<strong>Bioorg Med Chem.</strong>&nbsp;2014 Jan 15;22(2):673-83. PMID: 24393720</li>
<li>Elias HK, Schinke C, Bhattacharyya S, Will B*,&nbsp;<strong>Verma A*,&nbsp;</strong>&nbsp;Steidl U* *CoCorresponding,&nbsp;&nbsp;&nbsp; &ldquo;Stem cell origin of myelodysplastic syndromes.&rdquo;&nbsp;<strong>Oncogene</strong>&nbsp;2013 Dec 16. PMID: 24336326</li>
<li>Pathak S, Roth M,&nbsp;<strong>Verma A*,</strong>&nbsp;Steidl U*.&nbsp; *CoCorresponding,&nbsp;&nbsp;&nbsp; &ldquo;Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.&rdquo;<br />
<strong>Expert Opin Drug Metab Toxicol.</strong>&nbsp;2013 Dec;9(12):1667-75. PMID: 24215532</li>
<li>Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y,&nbsp;<strong>Verma AK,&nbsp;&nbsp;</strong>&ldquo;Linked-in: design and efficacy of antibody drug conjugates in oncology.&rdquo;&nbsp;<strong>Oncotarget</strong>&nbsp;2013 Mar;4(3):397-412. PMID: 23651630</li>
<li>Khan H, Vale C, Bhagat T,&nbsp;<strong>Verma A.,&nbsp;&nbsp;&nbsp;</strong>&ldquo;Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.&rdquo;<br />
<strong>Semin Hematol.</strong>&nbsp;2013 Jan;50(1):16-37. PMID: 23507481</li>
<li>Elias H,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.&rdquo;<br />
<strong>Leuk Lymphoma.</strong>&nbsp;2012 Dec;53(12):2337-8. PMID: 22897726</li>
<li>Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C,&nbsp;<strong>Verma A.,&nbsp;&nbsp;</strong>&ldquo;Alterations in the ribosomal machinery in cancer and hematologic disorders.&rdquo;&nbsp;<strong>J Hematol Oncol.</strong>&nbsp;2012 Jun 18;5:32. PMID: 22709827</li>
<li>Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A,&nbsp;<strong>Verma A.,&nbsp;&nbsp;</strong>&ldquo;Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.&rdquo;&nbsp;<strong>Int J Clin Exp Pathol.</strong>&nbsp;2012;5(5):382-96. PMID: 22808291</li>
<li>Sharma A,&nbsp; Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.&rdquo;&nbsp;<strong>WIREs Systems Biology and Medicine</strong>&nbsp;2010 Nov-Dec;2(6):654-69. PMID: 20890963</li>
<li>Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM,&nbsp;<strong>Verma A,&nbsp; &ldquo;</strong>Aberrant DNA methylation in malignant melanoma.&rdquo;&nbsp;<strong>Melanoma Research</strong>&nbsp;2010, Aug; 20(4):253-65 PMID: 20418788</li>
<li>Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B,&nbsp;<strong>Verma A.,&nbsp;</strong>&ldquo;Mechanism of action of lenalidomide in hematological malignancies.&rdquo;<br />
<strong>J Hematol Oncol.</strong>&nbsp;2009 Aug 12;2:36</li>
<li>Opalinska J, Zhou L,&nbsp;<strong>Verma A.,&nbsp;</strong>&ldquo;A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.&rdquo;&nbsp;<strong>Leukemia Research (Commentary)</strong>&nbsp;2007, 48(3):443</li>
<li>Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P,&nbsp;<strong>Verma A., &ldquo;</strong>Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.&rdquo;&nbsp;<strong>Journal of Interferon and Cytokine Research</strong>&nbsp;2007, 27(7):543</li>
<li>Mohindru M,&nbsp;<strong>Verma A,&nbsp;&nbsp;</strong>&ldquo;Engineered antibodies act as targeted therapies in cancer treatment.&rdquo;&nbsp;<strong>Indian Journal of Pediatrics,</strong>&nbsp;2005 Nov;72(11):943-7</li>
<li>Sassano A,&nbsp;<strong>Verma A,</strong>&nbsp;Platanias LC, "Mitogen-activated protein kinase pathways in interferon signaling."&nbsp;<strong>Methods Molecular Medicine,</strong>&nbsp;2005;116:135-50.</li>
<li>Mohindru M,&nbsp;<strong>Verma A,&nbsp;</strong>"Kinase inhibitors translate lab discoveries into exciting new cures for cancers."&nbsp;<strong>Indian Journal of Pediatrics,</strong>&nbsp;2004 Aug;71(8):713-8.</li>
<li><strong>Verma A,</strong>&nbsp;Kambhampati S, Parmar S, Platanias LC,&nbsp; &ldquo;Jak family of kinases in cancer.&rdquo;&nbsp;<strong>Cancer Metastasis Rev.</strong>&nbsp;2003 Dec;22(4):423-34.(rev)</li>
<li><strong>Verma A,</strong>&nbsp;and Platanias LC, &ldquo;Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.&rdquo;&nbsp;<strong>Leukemia and Lymphoma&nbsp;</strong>&nbsp;2002, 44:703-709</li>
<li><strong>Verma A,</strong>&nbsp;and Stock W, &ldquo;Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.&rdquo;&nbsp;<strong>Current Opinion in Oncology,</strong>&nbsp;2001, 13:14-20</li>
<li><strong>Verma A,</strong>&nbsp;and Gupta YK,&nbsp; &ldquo;The search for a super oral rehydration solution (0RS).&rdquo;&nbsp;<strong>Drugs: News and Views,</strong>&nbsp;1995, 3(2):129-132.&nbsp;</li>
</ol>

EMR ID

4772

Biography

<p>Amit K. Verma, MD, is Interim Chair, Department of Oncology, Associate Director of Translational Science, Montefiore Einstein Comprehensive Cancer Center, Professor, Medical Oncology and Professor, Developmental & Molecular Biology, Albert Einstein College of Medicine.</p><p>Dr. Verma earned his Doctor of Medicine at the All India Institute of Medical Sciences in 1995 and finished his training in internal medicine, hematology oncology and stem cell transplantation at the University of Illinois and Northwestern University in 2003.</p><p>Dr. Verma conducts clinical studies for patients with MDS and leukemia and offers a variety of clinical trials for these patients. He conducts laboratory research aimed at discovering new treatments for myelodysplastic syndromes (MDS) and leukemias, and his research has shown that the TGF-beta superfamily/smad, IRAK and MAP kinase pathways are overactivated in MDS. His work has led to clinical trials with Luspatercept, Galunisertib, CA4948, ARRY-614 and various other promising agents in MDS. DR. Verma&rsquo;s research has shown that MDS and leukemias are caused by aberrant leukemic stem cells and has identified novel targets against MDS/AML stem cells that are being tested in various studies.</p><p>Dr. Verma is a scholar of the Leukemia and Lymphoma society, elected member of American society of clinical investigation and his research is funded by the NIH, Department of Defense, American Cancer Society, Edward P. Evans Foundation and various other private foundations.</p>

Is Open Scheduling

Off

Ana Y. Valdivia

https://assets.montefioreeinstein.org/profiles/images/physphoto/Valdivia_Ana_MD_420x504.jpg

First Name

Ana

Last Name

Valdivia

NPI

1184728404

Faculty ID

8283

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Languages

Gender

Female

Email

Phone

Titles

Locations

Education and Trainings

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

EMR ID

4272

Biography

<p>Ana Y. Valdivia, MD, is an attending physician at Montefiore Einstein and Assistant Professor, Diagnostic Radiology at our Albert Einstein College of Medicine. Dr. Valdivia&rsquo;s clinical focus involves all aspects of nuclear medicine, with a particular focus on positron emission tomography&ndash;computed tomography (PET-CT).</p><p>After receiving her Bachelor of Science in chemistry at the University of Puerto Rico in 1990, Dr. Valdivia attended Universidad Central del Caribe School of Medicine, earning her Doctor of Medicine in 1994. She completed her internal medicine residency at Veterans Affairs Medical Center in 1997, followed by her nuclear medicine residency at Mount Sinai Medical Center in 1999.</p><p>Dr. Valdivia&rsquo;s research involves PET-CT, frequently focusing on brain imaging. She has shared her research through peer-reviewed journals, book chapters, abstracts, exhibits, and oral and poster presentations. She is also an invited reviewer for the International Journal of Surgery.</p><p>Dr. Valdivia is board certified by the American Board of Internal Medicine and the American Board of Nuclear Medicine. She is a member of the Society of Nuclear Medicine and the American College of Radiology.</p>

Is Open Scheduling

Off

Aaron Zev Tokayer

https://assets.montefioreeinstein.org/profiles/images/Tokayer_Aaron_MD_420x504.jpg

First Name

Aaron

Last Name

Tokayer

NPI

1336220755

Faculty ID

704

CMO Specialties

Clinical Terms

Employment Status

Per Diem

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p>Dr. Tokayer received his B.A. in from Yeshiva College and his M.D. from Albert Einstein College of Medicine of Yeshiva University. &nbsp;He completed an internship and residency at the Bronx Municipal Hospital Center and GI and Hepatology fellowship at Johns Hopkins Medical Center. He received an MHS degree in Clinical Epidemiology from Johns Hopkins School of Public Health. Dr. Tokayer then joined the Montefiore GI Faculty in 1992. He has been involved in the spectrum of clinical patient care, endoscopic interventions and teaching in the GI fellowship program. His areas of interest include clinical practice, patient care and education, endoscopic procedures and interventions, functional GI and motility disorders. He is Director of the GI Motility Lab where studies such as Esophageal Manometry,&nbsp; Esophageal Acid Monitoring and Impedance Testing, Ano-rectal Manometry and Defecatory Testing, Hydrogen Breath Testing for Bacterial overgrowth and Carbohydrate Maldigestion , and studies of gastric and intestinal transit. He works closely with colleagues of the Department of Radiology and Nuclear Medicine as well as the Department of Surgery in diagnosing and treating GI motility disorders.</p>

Research Profile

CHAM Provider

Off

Professional Title

Elsevier Profile

Is Open Scheduling

Off

Brendon M. Stiles

https://assets.montefioreeinstein.org/profiles/images/Stiles_Brendon_MD_2x.jpg

First Name

Brendon

Last Name

Stiles

NPI

1013176387

Faculty ID

16884

CMO Specialties

Clinical Terms

Employment Status

Full Time

Patient Type

Adult

Department

Gender

Male

Email

Phone

Titles

Locations

Education and Trainings

Professional Interests

<p class="MsoNoSpacing">Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic &amp; Vascular Surgery at Montefiore-Einstein.&nbsp; Dr. Stiles is also the Associate Director for Surgical Services in the Montefiore-Einstein Cancer Center. Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.</p>
<p class="MsoNoSpacing">Dr. Stiles is also heavily involved with translational and basic research.&nbsp; Translationally, Dr. Stiles is interested in neoadjuvant immunotherapy and in predicting and augmenting response to immunotherapy.&nbsp; &nbsp;In the laboratory, he has been funded by the AATS, TSF, the Lung Cancer Research Foundation, the DOD CDMRP Lung Cancer Research Program, and the Mark Foundation.&nbsp;</p>
<p class="MsoNoSpacing">Dr. Stiles' laboratory currently investigates the protein ART1, an extracellular mono-ADP-ribosyltransferase.&nbsp; Recently, Dr. Stiles and his team discovered that ART1 may play an important role in one mechanism of resistance in lung cancers. ART1 mono-ADP-ribosylates the P2X7 receptor (P2X7R) on immune cells, which ultimately causes NAD-induced cell death (NICD) in T cells, macrophages, and dendritic cells. They found ART1 to be highly expressed in multiple human non-small cell lung cancer cell lines and in the majority of human lung adenocarcinomas they sampled.<span style="mso-spacerun: yes;">&nbsp; </span>ART1 expression allows cancers to blunt the immune response against them. Indeed, they found that inhibiting ART1 with a therapeutic monoclonal antibody in mouse models of lung cancer caused a dramatic reduction of tumor burden and an enrichment of immune cells in the tumor.</p>
<p class="MsoNoSpacing"><span style="font-size: 12pt;">Current efforts are underway to better understand regulation of ART1 expression, to identify more targets of extracellular mono-ADP-ribosylation, and to refine pre-clincal models to test their therapeutic antibody targeting ART1.</span></p>
<p class="MsoNoSpacing">&nbsp;</p>
<p class="MsoNoSpacing">&nbsp;</p>

Research Areas

Specialties

Expert Tags

Areas of Expertise

Expert Summary

<p>Dr. Stiles’ clinical focus is on the treatment of lung and esophageal cancer and on neoadjuvant immunotherapy. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.
</p>

Research Profile

Clinical Profile

CHAM Provider

Off

Professional Title

Clinical Focus

Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases.&nbsp;<quillbot-extension-portal></quillbot-extension-portal>

Research Focus

Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.&nbsp; In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer.<quillbot-extension-portal></quillbot-extension-portal>

Elsevier Profile

Selected Publications

<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif;">Wennerberg, Erik et al, Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer.&nbsp;&nbsp;<em>Science Translational Medicine.&nbsp;</em>2022 Mar 16;14(636):eabe8195.&nbsp;&nbsp;</span><u style="font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 14px;"><span style="font-size: 11.0pt; font-family: 'Calibri',sans-serif; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; color: #0563c1; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><a href="https://nam04.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.s…;
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Altorki, Nasser K., et al. "The lung microenvironment: an important regulator of tumour growth and metastasis."&nbsp;</span><em style="font-size: 12pt;"><span style="font-family: Arial, sans-serif;">Nature Reviews Cancer</span></em><span style="font-size: 12pt;">&nbsp;19.1 (2019): 9-31.</span></p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Yao, Zhan, et al. "TGF-&beta; IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Proceedings of the National Academy of Sciences</span></em>&nbsp;107.35 (2010): 15535-15540.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Gao, Dingcheng, et al. "Myeloid progenitor cells in the premetastatic lung promote metastases by inducing mesenchymal to epithelial transition."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Cancer research</span></em>&nbsp;72.6 (2012): 1384-1394.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Altorki, Nasser K., et al. "Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: A single-centre, randomised phase 2 trial."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">The Lancet Oncology</span></em>&nbsp;22.6 (2021): 824-835.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Wennerberg, Erik, et al. "Expression of ART1, an extracellular mono ADP-ribosylase, promotes lung cancer growth and dissemination by limiting tumor infiltration of P2X7R+ CD8+ T cells and CD103+ dendritic cells."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">JOURNAL FOR IMMUNOTHERAPY OF CANCER</span></em>. Vol. 7. CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND: BMC, 2019.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">Chen, Chuang, et al. "ART1, an extracellular ADP-ribosyltransferase, is over-expressed in non-small cell lung cancer and facilitates cancer cell survival by immune-mediated mechanisms."&nbsp;</span><em><span style="font-family: Arial, sans-serif;">Journal of Thoracic Oncology</span></em>&nbsp;11.2 (2016): S44.</p>
<p style="margin-right: 0in; margin-left: 0in; font-size: 12pt; font-family: 'Times New Roman', serif;"><span style="font-family: Arial, sans-serif; color: #222222;">https://scholar.google.com/citations?user=fR4OkgkAAAAJ&amp;hl=en&amp;oi…;

EMR ID

82842

Biography

<p>Brendon Stiles, MD, is Professor and Chief, Thoracic Surgery and Surgical Oncology, Department of Cardiothoracic &amp; Vascular Surgery at Montefiore Einstein, and the Associate Director for Surgical Services in the Montefiore Einstein Cancer Center. Dr. Stiles&rsquo; clinical focus is on the treatment of lung and esophageal cancer and unusual thoracic cancers including metastatic tumors and those invading the heart. He also has a clinical interest in treating benign chest and upper gastrointestinal diseases. Taking a patient-first philosophy, Dr. Stiles provides world-class personalized care, using minimally invasive, organ-sparing techniques and targeting surgical therapy to the specific needs of the patient and his or her individual tumor.</p><p>&ldquo;The recruitment of&nbsp;Dr. Stiles elevates the treatment of lung cancer to a historic level,&rdquo; said Robert E. Michler, MD, Surgeon-in-Chief and Chairman and Professor, Department of Surgery and Department of Cardiothoracic &amp; Vascular Surgery at Montefiore-Einstein. &ldquo;Every thoracic surgical therapy available anywhere in the world will now be offered by Dr. Stiles at Montefiore-Einstein.&rdquo;</p><p>After earning his Bachelor of Arts in 1994 at the University of Virginia, Dr. Stiles continued at UVA, earning his Doctor of Medicine in 1999.&nbsp; He conducted his training in general surgery at the University of Virginia Health System. From 2001 to 2003, Dr. Stiles served as a surgical research fellow at Memorial Sloan-Kettering Cancer Center before returning to the University of Virginia Health System to complete his surgical residency. Dr. Stiles completed a cardiothoracic surgery residency at NewYork-Presbyterian Hospital-Weill Cornell and Memorial Sloan-Kettering Cancer Center in 2008. Dr. Stiles joined the faculty at NewYork-Presbyterian Hospital-Weill Cornell before being recruited by Dr. Michler to Montefiore-Einstein in 2021.</p><p>Dr. Stiles is actively involved in both clinical and translational research, particularly focusing on lung cancer. His clinical research concentrates on the management of early stage or screen detected lung cancer and on novel multidisciplinary treatment strategies for patients with lung cancer.&nbsp; In the laboratory, he investigates a protein called ART1 and its role in protecting cancer cells from the immune system. He has developed a novel drug targeting ART1 with a goal of advancing it to clinical use. He has co-authored numerous manuscripts on the management of early stage or screen-detected lung cancer, guidelines for the management of early stage lung cancer, papers regarding neoadjuvant immunotherapy for lung cancer patients and a comprehensive review on the tumor microenvironment in lung cancer. In addition to publications in peer-reviewed journals, he has also given several invited national and international talks on his research and on the clinical management of lung and esophageal cancer.</p><p>Dr. Stiles is highly active in the lung cancer care community, having lost his own father to lung cancer in 2005. He is committed to raising money for lung cancer research, serving as chair of the Lung Cancer Research Foundation since 2017. He is also an invited member of the National Lung Cancer Roundtable and on the Lung-RADS Steering Committee for lung cancer screening with the American College of Radiology.&nbsp; Dr. Stiles is a member of several professional organizations including the American Association for Thoracic Surgery, the Society of Thoracic Surgeons, the American Society of Clinical Oncology, the European Society of Thoracic Surgeons and the International Association for the Study of Lung Cancer.</p>

Is Open Scheduling

Off